• Restore CFTR FunctionEnrolling

  Study of galicaftor/navocaftor/ABBV-576 combination therapy in adults with cystic fibrosis who have at least one F508del mutation and are on stable elexacaftor/tezacaftor/ivacaftor (Trikafta) treatment. , protocol number Abbvie M19-771

  This study will look at the safety and effectiveness of the galicaftor/navocaftor/ABBV-576 combination therapy, a combination of CFTR modulators intended to help CFTR protein function closer to normal. This study is for adults with cystic fibrosis who have at least one F508del mutation.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    6

  • Length of Participation:

    3 months

• Restore CFTR FunctionEnrolling

  Study of Trikafta® in people with CF ages 12 years and older who have partial function CFTR mutations , protocol number Sorscher Partial Function Sub-Study

  This study will look at the effectiveness of Trikafta^®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta^® and evidence of partial CFTR function. Partial function is defined as a sweat chloride level < 80 mmol/L and/or pancreatic sufficiency (no pancreatic enzyme supplement therapy).

  • Age:

    12 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    5

  • Length of Participation:

    2 months

• Restore CFTR FunctionEnrolling

  Study of Trikafta® in people with CF ages 12 years and older who have an N1303K CFTR mutation , protocol number N1303K Sub-Study

  This study will look at the effectiveness of Trikafta, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta^® and a least one of these mutations must be N1303K.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    5

  • Length of Participation:

    86 days

• Restore CFTR FunctionClosed to Enrollment

  Phase 3 study of VX-121/tezacaftor/deutivacaftor in children ages 6 to 11 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort A1

  This study is taking place at multiple care centers across the U.S. It will look at safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation.

  • Age:

    6 Years to 11 Years

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    60% or greater

  • Number of Visits:

    8

  • Length of Participation:

    7 weeks

• Restore CFTR FunctionClosed to Enrollment

  Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part B) , protocol number VX20-445-111 PART B

  This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.

  • Age:

    2 Years to 5 Years

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    9

  • Length of Participation:

    32 weeks

• Restore CFTR FunctionClosed to Enrollment

  Study of VX-121 in people with CF ages 12 years and older who have either two copies of the F508del mutation, one copy of the F508del mutation and one copy of a gating or residual function mutation, or no copies of the F508del mutation and at least one other triple combination responsive CFTR mutation , protocol number Vertex VX20-121-103

  This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal.  

  • Age:

    12 Years and Older

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    64 weeks

• Restore CFTR FunctionClosed to Enrollment

  Study of VX-121 in people with CF ages 12 years and older who have one copy of the F508del mutation and one copy of a minimal function mutation , protocol number Vertex VX20-121-102

  This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal.

  • Age:

    12 Years and Older

  • Mutation(s):

    One Copy F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    10

  • Length of Participation:

    64 weeks

• Restore CFTR FunctionClosed to Enrollment

  Study of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor, in children 2-5 years old with cystic fibrosis (Part A) , protocol number Vertex VX20-445-111 Part A

  This study will look at the safety and effectiveness of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®), in children ages 2-5 years old with CF. These drugs are intended to help CFTR protein function closer to normal.

  • Age:

    2 Years to 5 Years

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    5

  • Length of Participation:

    53 days

• Restore CFTR FunctionClosed to Enrollment

  Study of ABBV-3067 and ABBV-2222 in adults with cystic fibrosis who have two copies of the F508del mutation , protocol number AbbVie M19-530

  This study will look at the safety and effectiveness of ABBV-3067, a CFTR modulator intended to help CFTR protein function closer to normal. ABBV-3067 will be tested alone and in combination with another CFTR modulator, ABBV-2222.

  • Age:

    18 Years and Older

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    5

  • Length of Participation:

    3 months

• Restore CFTR FunctionClosed to Enrollment

  Phase 3 study of lumacaftor/ivacaftor (Orkambi®) in babies with two copies of the F508del CFTR mutation (Part B) , protocol number Vertex VX-16-809-122 Part B

  This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (Orkambi®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.

  • Age:

    1 Years to 2 Years

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    11

  • Length of Participation:

    38 weeks

• Restore CFTR FunctionClosed to Enrollment

  Phase 3 study of lumacaftor/ivacaftor (Orkambi®) in babies with two copies of the F508del CFTR mutation , protocol number Vertex VX-16-809-122 Part A

  This study is taking place at multiple care centers across the U.S. It will evaluate the safety of the drug lumacaftor/ivacaftor (Orkambi®) and its effect on the body. It is for babies ages 1 to less than 2 years old who have cystic fibrosis and two copies of the F508del CFTR mutation.

  • Age:

    1 Years to 2 Years

  • Mutation(s):

    Two Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    5

  • Length of Participation:

    35 days

• Restore CFTR FunctionClosed to Enrollment

  RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion) , protocol number Translate Bio MRT5005-101

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.

  • Age:

    18 Years and Older

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    50 to 90%

  • Number of Visits:

    21

  • Length of Participation:

    1 years

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.